DXd-d 2

Overview

DXd -d2 2 (Exatecan derivative for ADC-d 2 ) is the deuterated-labeled DXd ( HY-13631D ). DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC 50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Antibody-Drug Conjugate/ADC Related | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Isotope-Labeled Compounds | Products > Signaling Pathways > Topoisomerase | Products > Signaling Pathways > ADC Payloads

Product Information

• Catalog No.: HY-13631DS1
• CAS No.: 2760715-90-8
• Molecular Formula: C26H22D2FN3O6
• Molecular Weight: 495.50
• Storage: -20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (5.05 mM); Clear solution
• Availability: In-stock

Source

Original product source